SAB Biotherapeutics (NASDAQ:SABS – Get Free Report) and CareDx (NASDAQ:CDNA – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, valuation, profitability and institutional ownership.
Valuation and Earnings
This table compares SAB Biotherapeutics and CareDx”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SAB Biotherapeutics | $1.32 million | 215.07 | $13.27 million | ($1.30) | -2.40 |
| CareDx | $379.80 million | 12.24 | -$21.35 million | $2.39 | 37.02 |
SAB Biotherapeutics has higher earnings, but lower revenue than CareDx. SAB Biotherapeutics is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for SAB Biotherapeutics and CareDx, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| SAB Biotherapeutics | 1 | 1 | 9 | 0 | 2.73 |
| CareDx | 0 | 5 | 3 | 0 | 2.38 |
SAB Biotherapeutics currently has a consensus price target of $12.00, suggesting a potential upside of 284.62%. CareDx has a consensus price target of $64.40, suggesting a potential downside of 27.21%. Given SAB Biotherapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe SAB Biotherapeutics is more favorable than CareDx.
Profitability
This table compares SAB Biotherapeutics and CareDx’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| SAB Biotherapeutics | N/A | -6.74% | -6.06% |
| CareDx | 25.86% | 9.74% | 7.35% |
Institutional & Insider Ownership
7.8% of SAB Biotherapeutics shares are held by institutional investors. 7.4% of SAB Biotherapeutics shares are held by insiders. Comparatively, 2.4% of CareDx shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Risk and Volatility
SAB Biotherapeutics has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500. Comparatively, CareDx has a beta of 2.51, meaning that its share price is 151% more volatile than the S&P 500.
Summary
SAB Biotherapeutics beats CareDx on 7 of the 13 factors compared between the two stocks.
About SAB Biotherapeutics
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing – human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.
About CareDx
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
